All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

End-stage renal disease (ESRD) is a significant public health issue worldwide, and this problem is compounded by limited access to renal replacement therapy (RRT) in developing countries \[[@pone.0152203.ref001]\]. Diabetes mellitus and hypertension are the major causes of ESRD in developed countries while glomerulonephritis (GN) is reported to overwhelmingly account for a high proportion of ESRD patients in developing countries \[[@pone.0152203.ref002]--[@pone.0152203.ref005]\]. The 2012 United States Renal data system (USRDS) shows that the adjusted ESRD incidence rates by primary cause for diabetes mellitus, hypertension and GN were 154.1/million/year, 101.1/million/year and 28.3/million/year respectively \[[@pone.0152203.ref002]\]. However, data from the Chinese Renal Data System show glomerular diseases as the most common cause of ESRD (57.4%) \[[@pone.0152203.ref003]\]. Studies from Africa have shown that glomerular diseases account for 10.2% to 52% of patients with ESRD \[[@pone.0152203.ref006]--[@pone.0152203.ref011]\].

The existence of well-established renal registries allows for definition and classification of the patterns of glomerular diseases in developed countries. For instance, IgA nephropathy is the commonest GN in Europe, North America and Asia \[[@pone.0152203.ref012]\]. With few renal registries in Africa, the patterns of renal diseases are not clearly defined due to limited data stemming from absence of relevant skills and expertise for performing renal biopsies, or appropriate tools and infrastructure to process the biopsy data when available. This creates an important gap about glomerular disease patterns in Africa despite GNs being the commonest cause of ESRD in the continent. We aimed to systematically review available published literature on the epidemiology of histologically proven glomerular diseases in Africa.

Materials and Methods {#sec006}
=====================

The review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework \[[@pone.0152203.ref013]\].

Selection of eligible studies, types of studies and sources of information {#sec007}
--------------------------------------------------------------------------

Relevant studies were identified by searching PubMed, AfricaWide and the Cumulative Index to Nursing and Allied Health Literature \[CINAHL) on EBSCO Host, Scopus, African Journals online (AJOL) databases, and the African Index Medicus. The search was limited to studies from African countries and to articles published between the 1^st^ of January, 1980 and 31^st^ December, 2014. The search strategy was not restricted to any language. The search was further enhanced by inspection of bibliographies of articles obtained from the databases search. Two authors (IGO and OIA) independently conducted the database searches. Abstracts from articles in French were assessed by two of the authors (OIA and APK). The reference list of articles that met the inclusion criteria were inspected for articles relevant to the review. Known regional experts in glomerular diseases were also contacted for possible additional articles that might be contained in various regional registries or unindexed local journals.

Search Strategy {#sec008}
---------------

The search strategy utilized four main themes to conduct the databases search:

-   Theme 1 was related to the disease of interest using Boolean operator "or" and the text-words that included "glomerulonephritis", "glomerulonephritides", "glomerular inflammation", and "glomerulosclerosis".

-   Theme 2 was related to the diagnostic method for the disease of interest i.e. "renal biopsy".

-   Theme 3 was related to the population of interest using Boolean operator "or" and the text-words "child\*", "pediatric\*", "paediatric\*", "adolescents\" and "adult"

-   Theme 4 was related to the all countries in the region of interest using Boolean operator "or", the text-words "Africa\*", and each individual country in the region.

Themes 1 to 4 were then combined in sequence with the Boolean operator "AND". The search strategy within PUBMED which had returned the highest results is depicted in ([S1 Table](#pone.0152203.s007){ref-type="supplementary-material"}).

Data Collection {#sec009}
---------------

Two authors (IGO and OIA) independently assessed all abstracts for eligibility. In situations of disagreements between the two reviewers, a third reviewer (APK) arbitrated for eligibility. The inclusion criteria was that a study had to: 1) be conducted amongst African populations residing in Africa; 2) report on only biopsy-proven cases of GN; 3) enrolled at least 50 participants; 4)provided data on the demographic distribution and histopathologic types of the reported GN. We excluded studies whose focus was on: transplant related GNs, in Africans residing on other continents, entire cohort had a single or specific histopathologic type of GN, a clinical syndrome of GN without renal biopsy, and GNs reported in autopsy samples. [Fig 1](#pone.0152203.g001){ref-type="fig"} shows the PRISMA study selection flowchart. A full text review of selected studies was then conducted to extract relevant data. Data collected included: year of publication, country and African region of publication, study design, number of biopsies performed, age at biopsy, gender distribution, indications for biopsy and the frequencies of reported glomerular diseases.

![PRISMA flow diagram of study selection.](pone.0152203.g001){#pone.0152203.g001}

Data Extraction and synthesis {#sec010}
-----------------------------

The studies were categorized into 3 groups (A, B or C) depending on whether the reporting was for adults only, combined adult and paediatric study or paediatric study only, respectively. The characteristics of the selected articles extracted include the main indication for renal biopsy, age of patients at the time of biopsy, the period over which the biopsies had been done, and the number of biopsies performed in the period. The average number of biopsies performed per study was calculated as the total number of biopsies over the entire period divided by the total duration of the study. The frequencies of primary and secondary GNs were determined. Secondary GNs selected for reporting were limited to lupus nephritis (LN), GNs related to human immunodeficiency virus (HIV) and hepatitis B viral infections and amyloidosis as these were the commonly reported forms of secondary GNs. Data extraction was done by one author (IGO) and another author (OIA) verified the accuracy and validity of extracted data. To generate the frequency of different GNs across studies, the DerSimonian-Laird random effects models were used to pool study level estimates overall and by geographic region \[North Africa, East and Central Africa, Southern Africa, and West Africa\]. To minimise the effect of extreme proportions on the overall estimates, we first stabilized the variance of the raw prevalence with a single arcsine transformation before pooling \[[@pone.0152203.ref014]\]. Heterogeneity across studies was assessed with the use of the Cochran Q and I^2^ statistics \[[@pone.0152203.ref015]\], while the Egger test of bias \[[@pone.0152203.ref016]\] was used to investigate the publication bias. All analyses used the R statistical software (version 3.0.3 \[2014-03-06\], The R Foundation for statistical computing, Vienna, Austria) and '*meta*' package (version 4.1--0).

Results {#sec011}
=======

Demographic and clinical features {#sec012}
---------------------------------

Twenty-four full papers were reviewed and analysed for this study \[[@pone.0152203.ref017]--[@pone.0152203.ref040]\]. Eight of the 24 studies (33.3%) reported on studies in adults (group A) \[[@pone.0152203.ref017]--[@pone.0152203.ref024]\], 11/24 (45.8%) comprised adults and paediatrics (group B) \[[@pone.0152203.ref025]--[@pone.0152203.ref035]\] and 5/24 studies (20.8%) were restricted to paediatric age groups (group C) \[[@pone.0152203.ref036]--[@pone.0152203.ref040]\]. Overall, 12,093 renal biopsies were reported in the 35 year period evaluated. The period of analysis ranged from as short as 12 months to up to 30 years and only 3 studies were found to have had a prospective design; no study was reported from a national renal biopsy registry. Most of the studies in all the groups had a male predominance: 45.2%--62.7% for studies in group A; 47.3%--64.3% for studies in group B and 53.0%--68.8% for studies in group C. The average age at time of biopsy for the studies in group A was less than 40 years, while group C studies had an average age less than 9.5 years. Overall, the median number of biopsies per study was 127.0 (50--4436), however, the rate of renal biopsies reported per year showed extensive variation (group A: 17.1/year to 134/year; group B: 7.9/year to 617/year and group C: 5.2/year to 83.1/year). Nephrotic syndrome was the most common indication for renal biopsy and in 11/24 studies (45.8%), nephrotic syndrome was the sole reason (100%) for performing a biopsy \[[@pone.0152203.ref018]--[@pone.0152203.ref020], [@pone.0152203.ref025]--[@pone.0152203.ref029], [@pone.0152203.ref034], [@pone.0152203.ref036]--[@pone.0152203.ref038]\] ([Table 1](#pone.0152203.t001){ref-type="table"}). Overall, 11/24 studies (45.8%) were published from the year 2000 onwards with 8 from North Africa, 2 from West Africa and 1 from Southern Africa \[[@pone.0152203.ref021]--[@pone.0152203.ref024], [@pone.0152203.ref031]--[@pone.0152203.ref035], [@pone.0152203.ref039], [@pone.0152203.ref040]\]. Eight studies did not use the special stains (immunofluorescence or immunohistochemistry or immunoperoxidase) for evaluation of renal histology \[[@pone.0152203.ref017], [@pone.0152203.ref019], [@pone.0152203.ref020], [@pone.0152203.ref025], [@pone.0152203.ref026], [@pone.0152203.ref028], [@pone.0152203.ref029], [@pone.0152203.ref035]\]. Two studies reported that the special stains were performed in Europe (UK and France) \[[@pone.0152203.ref030], [@pone.0152203.ref032]\].

10.1371/journal.pone.0152203.t001

###### Demographic features of patients in included studies.

![](pone.0152203.t001){#pone.0152203.t001g}

  Year of publication   Region                                                             Country        Author \[REF\]                                   Study period (duration)   Study design    Number of biopsies reported   Average age at biopsy (years)                      Males (%)   Biopsy rate (number/year)   Main indication for renal biopsy (%)
  --------------------- ------------------------------------------------------------------ -------------- ------------------------------------------------ ------------------------- --------------- ----------------------------- -------------------------------------------------- ----------- --------------------------- --------------------------------------
                        **Group A: Studies reporting adult biopsies only**                                                                                                                                                                                                                                                    
  1984                  West Africa                                                        Nigeria        Awunor-Renner et al \[[@pone.0152203.ref017]\]   NR (1 year)               NR              134                           NR (12--61)                                        55.2        134.0                       NS (50)
  1992                  West Africa                                                        Nigeria        Oviasu et al \[[@pone.0152203.ref018]\]          1982--1988 (7 years)      NR              120                           Males: 37.5 (19--60), Females: 29.6 (15--52)       56.7        17.1                        NS (100)
  1993                  East and Central Africa                                            Zaire          Pakasa et al \[[@pone.0152203.ref019]\]          1986--1989 (4 years)      NR              92                            30.9 ± 13.2                                        48.0        23.0                        NS (100)
  1993                  West Africa                                                        Nigeria        Ojogwu et al \[[@pone.0152203.ref020]\]          NR                        NR              88                            28.9 ± 8.6                                         60.2        NR                          NS (100)
  2008                  West Africa                                                        Senegal        Niang et al \[[@pone.0152203.ref021]\]           1993--2003 (11 years)     Retrospective   258                           28 (15--79)[\*](#t001fn002){ref-type="table-fn"}   NR          25.9                        NS (39.8)
  2011                  Southern Africa                                                    South Africa   Okpechi et al \[[@pone.0152203.ref022]\]         2000--2009 (10 years)     Retrospective   1,284                         36.8 ± 14.0                                        45.2        128                         NS (52.5)
  2012                  North Africa                                                       Morocco        Aatif et al \[[@pone.0152203.ref023]\]           2000--2007 (8 years)      Retrospective   161                           40.4 ± 15.0                                        62.7        20.1                        NS (60.3)
  2013                  North Africa                                                       Sudan          Nadium et al \[[@pone.0152203.ref024]\]          2010--2011 (1 year)       Prospective     71                            34.6 ± 18                                          54.9        71.0                        NS (46.5)
                        **Group B: Studies with combined adult and paediatric biopsies**                                                                                                                                                                                                                                      
  1980                  East and Central Africa                                            Kenya          Kung'u et al \[[@pone.0152203.ref025]\]          1970--1978 (9 years)      NR              150                           (1 --\>60)                                         50.7        16.7                        NR
  1981                  West Africa                                                        Ghana          Adu et al \[[@pone.0152203.ref026]\]             NR (4 years)              Retrospective   61                            Children: 7 (3--11), Adults: 26 (13--50)           59.0        15.3                        NS (100)
  1990                  East and Central Africa                                            Cameroon       Mbakop et al \[[@pone.0152203.ref027]\]          1986--1989 (4 years)      Retrospective   50                            (8--53)                                            NR          12.5                        NS (100)
  1993                  West Africa                                                        Nigeria        Kadiri et al \[[@pone.0152203.ref028]\]          1985--1990 (4.5 years)    NR              84                            10--59                                             64.3        18.7                        NS (100)
  1994                  East and Central Africa                                            Kenya          McLigeyo SO \[[@pone.0152203.ref029]\]           1982--1993 (12 years)     NR              422                           28.4 ± 9.2                                         49.5        35.2                        NS (100)
  1997                  Southern Africa                                                    Zimbabwe(\#)   Borok et al \[[@pone.0152203.ref030]\]           1982--1988 (6 years)      Prospective     119                           (3--52)                                            55.0        19.8                        NS (64.0)
  2000                  North Africa                                                       Egypt          Barsoum et al \[[@pone.0152203.ref031]\]         1998--1999 (2 years)      Retrospective   1,234                         30.5 ± 17.4                                        54.1        617                         NS (31.8)
  2001                  West Africa                                                        Senegal        Diouf et al \[[@pone.0152203.ref032]\]           1993--1998 (6 years)      Retrospective   115                           28 (5--60)                                         55.7        19.2                        NS (67.0)
  2006                  North Africa                                                       Tunisia        Ben Maiz et al \[[@pone.0152203.ref033]\]        1975--2005 (30 years)     Retrospective   4,436                         (≤15--≥65)                                         NR          147.9                       NR
  2011                  North Africa                                                       Morocco        Ayach et al \[[@pone.0152203.ref034]\]           2000--2009 (9.75 years)   Retrospective   77                            (12--25)                                           61.0        7.9                         NS (100)
  2012                  North Africa                                                       Egypt          Ibrahim et al \[[@pone.0152203.ref035]\]         2003--2008 (5 years)      Retrospective   924                           26.5 ± 14.6                                        47.3        184.8                       Proteinuria (43.1)
                        **Group C: Studies reporting paediatric biopsies only**                                                                                                                                                                                                                                               
  1990                  West Africa                                                        Nigeria        Abdurrahman et al \[[@pone.0152203.ref036]\]     NR (4years)               Prospective     98                            5.8 (1--12yrs)                                     53.0        24.5                        NS (100)
  1997                  Southern Africa                                                    South Africa   Bhimma et al \[[@pone.0152203.ref037]\]          NR (20 years)             Retrospective   480                           5.7 (2weeks--16 years)                             68.8        24.0                        NS (100)
  1999                  Southern Africa                                                    Namibia        Van Buuren et al \[[@pone.0152203.ref038]\]      1975--1988 (13 years)     Retrospective   68                            7.2 (1.8--15)                                      68.6        5.2                         NS (100)
  2010                  North Africa                                                       Sudan          Abdelraheem et al \[[@pone.0152203.ref039]\]     2002--2007 (6 years)      Retrospective   321                           8.7 (2 months--16 years)                           60.2        53.5                        NS (62.9)
  2014                  North Africa                                                       Egypt          Bakr et al \[[@pone.0152203.ref040]\]            1998--2012 (15 years)     Retrospective   1246                          9.2 ± 3.7                                          53.9        83.1                        NS (48.5)

NR--Not reported; NS--Nephrotic syndrome; (\#)--Biopsies were performed in Zimbabwe but the specimens were processed at St Mary's Hospital, UK

\* Median age (minimum--maximum).

Distribution of glomerular disease patterns {#sec013}
-------------------------------------------

[Table 2](#pone.0152203.t002){ref-type="table"} shows regional differences of types of GN as reported from the various studies. The proportion of biopsies performed for the search period per region was 70.0%, 16.1%, 7.9% and 5.9% for North Africa, Southern Africa, West Africa and East and Central Africa respectively. With the exception of diffuse proliferative GN (DPGN) (p = 0.0005), the contribution of primary aetiologies to the distribution of GNs across regions was mostly similar (all p≥0.099 for regional differences). With regard to secondary GNs, significant regional differences were apparent (all p\<0.052), although some comparisons were based on very few outcomes. For both primary and secondary GNs, there was indication of significant within region heterogeneities for some of the outcomes. But within region heterogeneities have to be interpreted against the background of small number of eligible studies within regions.

10.1371/journal.pone.0152203.t002

###### Frequencies of glomerular diseases by African regions.

![](pone.0152203.t002){#pone.0152203.t002g}

  GN Type               Regions   N studies   N biopsies   N outcomes   \% (95% CI)         I^2^   P heterogeneity   p-diff Regions
  --------------------- --------- ----------- ------------ ------------ ------------------- ------ ----------------- ----------------
  **MCD**               ECAf      4           714          139          20.6 (15.0--26.8)   66.3   0.031             0.406
                        NAf       7           4034         612          22.5 (12.6--34.3)   98.4   \<0.0001          
                        SAf       4           1951         211          11.2 (0.3--34.5)    99.1   \<0.0001          
                        WAf       8           958          127          12.2 (4.4--23.1)    95.0   \<0.0001          
  **MesPGN**            ECAf      2           472          109          14.7 (1.5--38.1)    92.7   0.0002            0.771
                        NAf       5           2711         249          7.0 (4.0--10.8)     89.2   \<0.0001          
                        SAf       3           1832         127          8.9 (4.9--14.1)     87     0.0005            
                        WAf       3           287          29           9.5 (1.5--23.3)     90.6   \<0.0001          
  **MCGN**              ECAf      4           714          65           9.1 (7.1--11.3)     0      0.822             0.087
                        NAf       7           8393         785          9.7 (6.6--13.4)     95.1   \<0.0001          
                        SAf       4           1951         130          6.4 (3.8--9.6)      75.8   0.006             
                        WAf       7           843          161          20.7 (8.9--35.7)    95.8   \<0.0001          
  **FSGS**              ECAf      4           714          118          15.5 (5.7--29.0)    93.4   \<0.0001          0.889
                        NAf       7           4034         543          13.2 (9.5--17.5)    91.4   \<0.0001          
                        SAf       4           1951         212          14.5 (2.8--33.2)    98.5   \<0.0001          
                        WAf       8           958          265          19.1 (5.9--37.4)    97.6   \<0.0001          
  **MGN**               ECAf      4           714          74           12.5 (7.1--19.2)    78.3   0.0032            0.142
                        NAf       8           8470         649          5.7 (2.2--10.5)     98.1   \<0.0001          
                        SAf       4           1951         127          5.7 (2.1--9.9)      89.4   \<0.0001          
                        WAf       8           958          70           5.9 (3.0--9.6)      78.1   \<0.0001          
  **IgAN**              ECAf      1           50           0            0.0 (0.0--1.9)      \-     \-                0.099
                        NAf       6           7469         332          3.8 (1.6--6.9)      96     \<0.0001          
                        SAf       1           1284         26           2.0 (1.3--2.9)      \-     \-                
                        WAf       1           115          2            1.7 (0.2--4.9)      \-     \-                
  **PIGN**              ECAf      1           50           0            0.0 (0.0--1.9)      \-     \-                0.102
                        NAf       2           482          81           10.3 (0.0--41.3)    98.4   \<0.0001          
                        SAf       2           1352         38           2.8 (2.0--3.7)      0      0.431             
                        WAf       1           115          3            2.6 (0.5--6.3)      \-     \-                
  **CresGN**            ECAf      3           622          41           3.9 (0.6--10.0)     85.2   0.0012            0.565
                        NAf       3           2641         32           1.4 (0.5--27.4)     80.2   0.0064            
                        SAf       2           1403         52           2.4 (0.2--6.6)      80.6   0.023             
                        WAf       4           467          7            1.1 (0.05--3.4)     68.7   0.023             
  **DPGN**              ECAf      4           714          82           10.3 (4.1--18.8)    88     \<0.0001          0.0005
                        NAf       5           8001         602          4.6 (1.1--10.2)     98.7   \<0.0001          
                        SAf       1           119          28           23.5 (16.4--31.5)   \-     \-                
                        WAf       5           497          98           17.8 (9.1-28-7)     88.2   \<0.0001          
  **FPGN**              ECAf      1           422          6            1.4 (0.5--2.8)      \-     \-                0.134
                        NAf       3           3404         251          6.5 (2.1--13.2)     97.8   \<0.0001          
                        SAf       1           119          4            3.4 (0.9--7.3)      \-     \-                
                        WAf       4           399          13           2.3 (0.1--7.2)      82.9   0.0006            
  **Lupus Nephritis**   ECAf      1           422          6            1.4 (0.5--2.8)      \-     \-                \<0.0001
                        NAf       6           8322         1122         13.9 (8.9--19.9)    97.6   \<0.0001          
                        SAf       3           1471         254          6.1 (0.0--22.5)     96.8   \<0.0001          
                        WAf       4           554          19           3.0 (0.1--9.8)      90.6   \<0.0001          
  **Hep B**             ECAf      1           422          0            0.0 (0.0--0.2)      \-     \-                \<0.0001
                        NAf       1           321          10           3.1 (1.5--5.3)      \-     \-                
                        SAf       3           1832         116          14.5 (0.7--41.2)    99.1   \<0.0001          
                        WAf       3           352          53           11.0 (0.0--39.4)    97.6   \<0.0001          
  **HIVAN**             ECAf      None        \-           \-           \-                  \-     \-                0.233
                        NAf       1           321          0            0.0 (0.0--0.3       \-     \-                
                        SAf       2           1764         145          2.9 (0.0--23.6)     99.4   \<0.0001          
                        WAf       1           258          1            0.4 (0.0--1.5)      \-     \-                
  **Amyloid**           ECAf      3           664          15           3.0 (0.2--6.7)      88     0.0002            0.052
                        NAf       6           8078         559          4.3 (1.4--8.6)      97.9   \<0.0001          
                        SAf       2           1403         16           1.1 (0.6--1.8)      0      0.596             
                        WAf       6           772          18           2.2 (1.3--3.4)      0      0.638             

MCD--Minimal change disease; MesPGN--Mesangial proliferative GN, MCGN--Mesangiocapillary GN; FSGS--Focal segmental glomerulosclerosis; MGN--Membranous GN; IgAN--Ig A nephropathy; PIGN--Post-infectious GN; CresGN--Crescentic GN; DPGN--Diffuse proliferative GN; FPGN--Focal proliferative GN; Hep. B--Hepatitis B; HIVAN--Human immunodeficiency virus associated nephropathy, WAf--West Africa, ECAf--East and Central Africa, SAf--Southern Africa, NAf--North Africa.

The prevalence of the various GNs according to countries and age at time of diagnosis is summarized in Figs [2](#pone.0152203.g002){ref-type="fig"} and [3](#pone.0152203.g003){ref-type="fig"} and in [S1](#pone.0152203.s002){ref-type="supplementary-material"}--[S5](#pone.0152203.s006){ref-type="supplementary-material"} Figs. The overall prevalence of minimal change disease (MCD) was the highest of all GNs reported by all 24 studies at 16.5% (95%CI: 11.2--22.6; n = 7657; p-heterogeneity \<0.0001). The highest prevalence of MCD was from a group B study in Morocco: 79.2% (68.5--87.6) \[[@pone.0152203.ref034]\] while 2 studies from Nigeria reported the lowest prevalence \[[@pone.0152203.ref017], [@pone.0152203.ref028]\]. Paediatric studies (group C) had the highest prevalence of MCD (compared to group A and B) but there was no significant difference across age groups (p = 0.496) ([Fig 2A](#pone.0152203.g002){ref-type="fig"}). There was no significant regional difference in overall prevalence of MCD in Africa (p = 0.406) although North Africa and East and Central African countries had the highest prevalence of MCD ([Table 2](#pone.0152203.t002){ref-type="table"}).

![Forest plot for random-effects meta-analyses for MCD and FSGS.\
This figure shows the pooled prevalence of minimal change disease (2A) and focal segmental glomerulosclerosis (2B) overall and by age group (MCD--minimal change disease, FSGS--focal segmental glomerulosclerosis).](pone.0152203.g002){#pone.0152203.g002}

![Forest plot for random-effects meta-analyses for hepatitis B related GNs and lupus nephritis.\
This figure shows the pooled prevalence of hepatitis B related GNs (3A) and lupus nephritis (3B) overall and by age group.](pone.0152203.g003){#pone.0152203.g003}

The overall prevalence of focal segmental glomerulosclerosis (FSGS) pattern was 15.9% (11.3--21.1; p-heterogeneity \<0.0001) ([Fig 2B](#pone.0152203.g002){ref-type="fig"}). Two studies from Senegal reported the highest prevalence rates: 51.9% (45.7--58.2) \[[@pone.0152203.ref021]\] and 47.0 (37.6--56.5) \[[@pone.0152203.ref032]\]. Awunnor-Renner et al \[[@pone.0152203.ref017]\] reported the lowest prevalence from adults in Zaria, Nigeria: 0.7% (0.0--4.1) while the lowest prevalence in paediatric studies was also reported from another study from Zaria, Nigeria \[[@pone.0152203.ref036]\]. However, other studies from Nigeria reported prevalence rates as high as 27.3% \[[@pone.0152203.ref020]\]. The prevalence of FSGS according to regions was highest for West Africa: 19.1% (5.9--37.4) and lowest for North Africa: 13.2% (9.5--17.5) but without significant interregional differences (p = 0.889) ([Table 2](#pone.0152203.t002){ref-type="table"}).

The prevalence of other reported primary GN patterns were: 9.2% (95%CI: 6.2--12.7; p-heterogeneity \<0.0001, difference across age groups: p = 0.511) for mesangial proliferative GN (MesPGN), 11.8% (95%CI: 9.2--14.6; p-heterogeneity \<0.0001, difference across age groups: p = 0.435) for mesangiocapillary GN (MCGN), 6.6% (95%CI: 4.6--9.0; p-heterogeneity \<0.0001, difference across age groups: p = 0.0001) for membranous GN (MGN), 2.8% (95%CI: 1.3--4.9; p-heterogeneity \<0.0001, differences across age groups: p = 0.0039) for IgA nephropathy (IgAN), 3.5% (95%CI: 0.2--10.9; p-heterogeneity \<0.0001, differences across age groups: p = 0.467) for post-infectious GN (PIGN), 2.0% (95%CI: 0.9--3.5; p-heterogeneity \<0.0001, differences across age groups: p = 0.862) for crescentic GN, 10.7% (95%CI: 6.8--15.3; p-heterogeneity \<0.0001, differences across age groups: p = 0.096) for DPGN and 3.6% (95%CI: 1.4--6.8; p-heterogeneity \<0.0001, differences across age groups: p\<0.0001) for focal proliferative GN (FPGN). Only 4 primary disease patterns (MCD, MCGN, FSGS and MGN) were reported from more than 20 of the 24 studies. There was no evidence of publication bias across all studies on primary GNs, all p≥0.143 for the Egger test of bias ([S1](#pone.0152203.s002){ref-type="supplementary-material"}--[S4](#pone.0152203.s005){ref-type="supplementary-material"} Figs).

Glomerular diseases related to hepatitis B virus infection had the highest prevalence among the reported secondary GNs: 8.4% (95% CI: 2.0--18.4; p-heterogeneity \<0.0001, differences across age groups: p\<0.0001) ([Fig 3A](#pone.0152203.g003){ref-type="fig"}). Lupus nephritis (LN) had the second highest prevalence: 7.7% (95%CI: 4.5--11.7; p-heterogeneity \<0.0001, differences across age groups: p\<0.0001) ([Fig 3B](#pone.0152203.g003){ref-type="fig"}). The high prevalence of LN was due to the high prevalence from studies from North Africa (p for difference across regions \<0.0001). Surprisingly, the human immunodeficiency virus associated nephropathy (HIVAN) had an overall prevalence of 1.0% (95%: 0.0--9.0; p-heterogeneity \<0.0001, differences across age groups: p\<0.0001). Amyloid was present in 2.9%. There was no evidence of publication bias, all p≥0.082 for the Egger test of bias ([Fig 3](#pone.0152203.g003){ref-type="fig"}, [S5A and S5B Fig](#pone.0152203.s006){ref-type="supplementary-material"}). [Fig 4A and 4B](#pone.0152203.g004){ref-type="fig"} shows the crude prevalence of primary and secondary GNs in North Africa and sub-Saharan Africa (SSA) with MCGN as the commonest primary GN in North Africa (9.3%) while FSGS is the most common in SSA (16.4%). Of the secondary GNs, LN was more common in North Africa while all reported HIVAN was from SSA.

![Regional differences (North Africa vs sub-Saharan Africa) in the prevalence of GNs.\
This figure shows the regional differences in the prevalence of primary GNs (4A) and secondary GNs (4B) for North Africa and sub-Saharan Africa.](pone.0152203.g004){#pone.0152203.g004}

Discussion {#sec014}
==========

There is paucity of reliable data on the epidemiology of ESRD in many parts of Africa partly due to the unavailability of renal registries. In Africa, glomerular diseases have been reported to account for a large proportion of patients with ESRD from several studies (reviewed in Maoujoud et al) \[[@pone.0152203.ref005]\]; in many of such studies, the diagnosis of GN may have been assumed given that late presentation of patients is common in Africa. In this review, we have found that: (i) most renal biopsies reported from Africa originates from studies in North Africa, (ii) MCD, FSGS and MCGN are the most common patterns of glomerular diseases reported in Africa, (iii) Hepatitis B and LN are common and important secondary causes of GNs and (iv) lack of standard and consistency in reporting renal biopsies.

Of the 12,093 biopsies that were reported, 70% were from studies carried out in North Africa and these countries had more papers published after the year 2000 compared to countries from sub-Sahara Africa. Due to cost (out-of-pocket payment), absence of skills for performing biopsies, handling of tissue and adequate interpretation of histology few centres in Africa are able to regularly perform renal biopsies (IGO, one of the co-authors can personally confirm this from meetings as an ISN educational ambassador in Africa).

Overall, MCD, FSGS and MCGN patterns of glomerular diseases were the most frequently reported GNs. This may be because in 11 of the 24 studies, nephrotic syndrome was the sole indication for performing a renal biopsy \[[@pone.0152203.ref018]--[@pone.0152203.ref020], [@pone.0152203.ref026]--[@pone.0152203.ref029], [@pone.0152203.ref034], [@pone.0152203.ref036]--[@pone.0152203.ref038]\] and these conditions are common causes of nephrotic syndrome. We observed that only six studies \[[@pone.0152203.ref017], [@pone.0152203.ref022]--[@pone.0152203.ref024], [@pone.0152203.ref034], [@pone.0152203.ref040]\] differentiated the glomerular disease patterns into primary and secondary causes. Hence, the proportion of the reported diagnoses/patterns that were truly of primary cause is unclear. For instance, although a number of studies in this review showed that MCGN is common, recent reports \[[@pone.0152203.ref041]\] have proven the rarity of true primary MCGN if appropriate diagnostic algorithms were applied. However, one study from South Africa reported primary MCGN to be common after an exhaustive search for secondary causes and also reported poor prognostic factors associated with MCGN \[[@pone.0152203.ref042]\]. We think that the high prevalence of FSGS may be related to a limited evaluation for secondary causes. A key study by Van Rensburg et al from Bloemfontein South Africa found FSGS to be the most common histological diagnosis in a 10 year review of medical renal diseases \[[@pone.0152203.ref043]\], but they reported that all FSGS (including HIV) were grouped together. The role of genetic factors such as the APOL-1 which have been shown to be strongly associated with FSGS (either primary or secondary association with HIV) in Africans \[[@pone.0152203.ref044], [@pone.0152203.ref045]\] supports our observation of an increased prevalence of FSGS in Africa.

Sub-Sahara Africa has the highest prevalence of hepatitis B virus infection in comparison to other regions in the world \[[@pone.0152203.ref046]\], hence this may account for the high prevalence of GNs related to hepatitis B infection. Glomerular diseases associated with hepatitis B were common in children from West and Southern Africa \[[@pone.0152203.ref036]--[@pone.0152203.ref038]\]. We speculate that the observed prevalence may be much lower than true prevalence due to under-reporting of cases. However, the studies \[[@pone.0152203.ref017], [@pone.0152203.ref018], [@pone.0152203.ref022], [@pone.0152203.ref029], [@pone.0152203.ref036]--[@pone.0152203.ref039]\] that reported GNs in hepatitis B positive patients did not show direct evidence for viral particles in the glomerulus. The result of the meta-analysis done for secondary GNs is perhaps related to the low performance and reporting of renal biopsies. Further, sub-Saharan Africa still bears an inordinate share of the global HIV burden. In 2014, that number reached 25.8 million \[24.0 million --28.7 million\], 70% of the global burden of HIV \[[@pone.0152203.ref047]\]. Given the very high HIV burden in SSA, HIVAN would be expected to be the secondary GN with the highest prevalence. However, this was not the case partly due to underperformance and reporting of renal biopsies across Africa. We have previously reported a rising incidence in biopsies associated with HIV in Cape Town from 6.6% in 2000 to 25.7% in 2009 \[[@pone.0152203.ref022]\] and this trend may apply to other countries with a high burden of HIV. Also, many studies from Africa describe renal disease in HIV positive patients without performing a renal biopsy. For example, Emem et al from Nigeria described the prevalence, clinical features and risk factors of renal disease in 400 consecutive HIV/AIDS patients presenting to their centre. However, only 10 patients had a renal biopsy out of which 7 (70%) had FSGS and the histology in others were reported as normal \[[@pone.0152203.ref048]\].

Similarly, LN is increasingly diagnosed in Africans especially from South Africa and countries of North Africa. The study from Tunisia clearly showed a changing pattern in the epidemiology GN over time and suggested that improving socio-economic factors might have played a role in the increasing prevalence of LN and IgA nephropathy while conditions often associated with chronic infections (e.g. MCGN and Amyloidosis) had reduced within three decades \[[@pone.0152203.ref033]\]. A disease entity we did not find reported during the assessed period was "malaria nephropathy" which used to be commonly reported from studies in the 60s and 70s \[[@pone.0152203.ref049], [@pone.0152203.ref050]\]. Whether this is related to improving socio-demographic factors or better and clearer diagnostic methods is not known. However, a number of authors have recently disputed the evidence for malarial nephropathy \[[@pone.0152203.ref051], [@pone.0152203.ref052]\].

We acknowledge key limitations of this work including lack of immunofluorescence technology in most of the studies and the absence of uniformity in describing pathologic patterns. For instance, most studies published before the year 2000 often referred to diffuse proliferative and focal proliferative GNs without further elaboration of the pattern (e.g. crescentic, necrotizing lesions or vasculitis). As many of the studies did not say if further serological, immunohistochemistry or immunofluorescence tests were conducted, some of the reported cases of DPGN / FPGN may have fallen under categories such as crescentic GN or PIGN.

Further, the small number of studies and studies with limited samples precluded careful investigation of the substantial heterogeneities observed across studies by subgroup and meta-regression analyses. It is known, however that statistical approaches to assessing heterogeneity could yield spurious results within uncontrolled studies. Hence, given that many of the studies included in this review were inherently weak, caution must be exercised in the interpretation of the results especially with regard to the prevalence of HIVAN as observed and reported. Although this is a weakness of this study, we are however confident that the results present a perspective of GN types commonly encountered in Africa. Although the performance of renal biopsies is necessary for diagnosis of GNs, we also acknowledge that this is not feasible in most African countries where the facilities and expertise are limited. There is therefore an urgent need to support initiatives (such as the ISN's educational ambassador program) to improve the expertise in renal biopsy performance, tissue processing and interpretation especially in SSA where this skill is typically absent. By doing this, renal biopsy registries are likely to become developed in Africa. This is not impossible despite the numerous challenges and will enhance our understanding of the epidemiology of GNs in Africa.

In conclusion, GNs in Africa are poorly characterized, especially in sub-Saharan Africa where the number of diagnostic biopsies performed has continued to decline over the last decade. Understanding the epidemiology of GNs in Africa is vital for an optimal care of patients with such conditions that are frequently associated with ESRD in this region. This could impact positively on CKD management in Africa as GNs are amenable to treatment in instances where they are diagnosed early enough. There is need to develop initiatives that assist in improving the expertise in renal biopsy performance, tissue processing and interpretation in Africa.
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###### Forest plot for random-effects meta-analyses for MCGN and MesPGN.

This figure shows the pooled prevalence of mesangiocapillary GN \[MCGN\] (1A) and mesangial proliferative GN \[MesPGN\] (1B) overall and by age group.
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###### Forest plot for random-effects meta-analyses for MGN and IgAN.

This figure shows the pooled prevalence of membranous GN \[MGN\] (2A) and IgA nephropathy \[IgAN\] (2B) overall and by age group.
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###### Forest plot for random-effects meta-analyses for crescentic GN and PIGN.

This figure shows the pooled prevalence of crescentic GN (3A) and post-infectious GN \[PIGN\] (3B) overall and by age group.
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###### Forest plot for random-effects meta-analyses for DPGN and FPGN.

This figure shows the pooled prevalence of diffuse proliferative GN \[DPGN\] (4A) and focal proliferative GN \[FPGN\] (4B) overall and by age group.
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###### Forest plot for random-effects meta-analyses for HIVAN and Amyloidosis.

This figure shows the pooled prevalence of HIV associated nephropathy \[HIVAN\] (5A) and amyloidosis (5B) overall and by age group.

(PPTX)

###### 

Click here for additional data file.

###### PUBMED search strategy.

(DOCX)

###### 

Click here for additional data file.

We wish to thank the following people for assisting us to retrieve some publications from their countries: Prof A. Niang (Senegal), Prof E. Oviasu (Nigeria), Drs A. Aje and Yemi Raji (Nigeria) and Prof M. Benghanem-Gharbi (Morocco).

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: IGO OIA AKB PR CRS APK. Performed the experiments: IGO OIA APK. Analyzed the data: IGO OIA AKB PR CRS APK. Wrote the paper: IGO OIA AKB PR CRS APK.
